Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs NATURAL ESTROGENIC SUBSTANCE-ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive. Ethinyl estradiol and levonorgestrel inhibit gonadotropin release (FSH, LH), suppressing ovulation. Progestin effect: thickens cervical mucus, alters endometrial receptivity. Ferrous fumarate provides iron supplementation during placebo phase.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol, 75 mg ferrous fumarate) orally once daily at the same time for 21 consecutive days, followed by one ferrous fumarate-only tablet (75 mg) orally once daily for 7 days (28-day cycle).
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
None Documented
None Documented
Levonorgestrel: ~25 hours, steady-state after 5 days. Ethinyl estradiol: ~13 hours (7–20). Ferrous fumarate: not applicable.
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Levonorgestrel: ~45% renal, ~32% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Ferrous fumarate: iron excreted in feces as unabsorbed; minimal renal.
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Category D/X
Category C
Estrogen
Estrogen